AI will be essential to hastening the process of discovering new drugs, facilitating precision medicine, and fostering a healthcare system that is more intelligent and driven by innovation, according to experts.
The emphasis of the pharmaceutical industry was on rethinking processes rather than just digitizing old ones. They emphasized the increasing significance of robust data and technological infrastructure for facilitating the widespread use of AI and emphasized the immediate advantages of automation in enhancing clinical efficiency.
On the first day of the ninth ‘India Pharma 2026,’ four impactful plenary discussions brought together industry leaders, regulators, politicians, and technology specialists to discuss the future of India’s pharmaceutical and life sciences sector.
The pressing need to close the gap between policy goals and on-the-ground implementation was emphasized during the first plenary meeting.
Industry-led research and development model, the need to improve government lab networks, and the need to align regulatory models with European systems were all highlighted by Manoj Joshi, Secretary, Department of Pharmaceuticals.
Despite the fact that research funding has grown significantly over the past few years, Rajiv Bahl, Secretary, Department of Health Research, stated that the nation requires a Bharat model of R&D that fosters confidence in the innovators and promotes greater collaboration between industry and academia.
Industry leaders echoed the necessity for more venture capital involvement and co-funding strategies to support research-driven businesses, closer industry-academia integration, and highlighted the significance of integrated ecosystems to convert early-stage discoveries into worldwide solutions, according to the Ministry of Chemicals and Fertilizers.
The main goal of the second plenary session was to establish a regulatory environment that is predictable, effective, and consistent with international standards.
The Drug Controller General of India, Dr. Rajeev Singh Raghuvanshi, emphasized the value of stakeholder input in developing effective regulatory frameworks.
The third plenary session addressed the revolutionary potential of artificial intelligence throughout the pharmaceutical value chain.
India’s expanding participation in the worldwide Contract Research, Development, and Manufacturing Organization (CRDMO) market was the subject of the fourth session.
India’s CRDMO industry, which is now worth approximately $8 billion, has been expanding at a healthy rate of 10–12% annually, according to the panel, indicating a strong demand for outsourcing worldwide.